{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T10:27:58Z","timestamp":1779272878091,"version":"3.51.4"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,2,24]],"date-time":"2013-02-24T00:00:00Z","timestamp":1361664000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1007\/s11255-013-0401-7","type":"journal-article","created":{"date-parts":[[2013,2,23]],"date-time":"2013-02-23T13:44:11Z","timestamp":1361627051000},"page":"239-242","source":"Crossref","is-referenced-by-count":26,"title":["Thrombotic microangiopathy due to acquired ADAMTS13 deficiency in a patient receiving interferon-beta treatment for multiple sclerosis"],"prefix":"10.1007","volume":"46","author":[{"given":"Corentin","family":"Orvain","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Fran\u00e7ois","family":"Augusto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virginie","family":"Besson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillaume","family":"Marc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Coppo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Fran\u00e7ois","family":"Subra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johnny","family":"Sayegh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,2,24]]},"reference":[{"key":"401_CR1","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1146\/annurev.pathmechdis.3.121806.154311","volume":"3","author":"XL Zheng","year":"2008","unstructured":"Zheng XL, Sadler JE (2008) Pathogenesis of thrombotic microangiopathies. Annu Rev Pathol Mech Dis 3:249\u2013277","journal-title":"Annu Rev Pathol Mech Dis"},{"issue":"4","key":"401_CR2","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/00005792-200207000-00008","volume":"81","author":"J Zuber","year":"2002","unstructured":"Zuber J, Martinez F, Droz D et al (2002) Alpha-interferon-associated thrombotic microangiopathy: a clinicopathologic study of 8 patients and review of the literature. Medicine 81(4):321\u2013331","journal-title":"Medicine"},{"issue":"8","key":"401_CR3","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1212\/WNL.53.8.1622","volume":"53","author":"EU Walther","year":"1999","unstructured":"Walther EU, Hohlfeld R (1999) Multiple sclerosis: side effects of interferon beta therapy and their management. Neurology 53(8):1622\u20131627","journal-title":"Neurology"},{"issue":"5","key":"401_CR4","doi-asserted-by":"crossref","first-page":"396","DOI":"10.5414\/CN106523","volume":"76","author":"A Broughton","year":"2011","unstructured":"Broughton A, Cosyns JP, Jadoul M (2011) Thrombotic microangiopathy induced by long-term interferon-B therapy for multiple sclerosis: a case report. Clin Nephrol 76(5):396\u2013400","journal-title":"Clin Nephrol"},{"issue":"17","key":"401_CR5","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJMra0902814","volume":"361","author":"M Noris","year":"2009","unstructured":"Noris M, Remuzzi G (2009) Atypical hemolytic-uremic syndrome. N Engl J Med 361(17):1676\u20131687","journal-title":"N Engl J Med"},{"issue":"2","key":"401_CR6","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.gcb.2007.12.019","volume":"32","author":"M Sall\u00e9e","year":"2008","unstructured":"Sall\u00e9e M, Cr\u00e9tel E, Jean R et al (2008) Thrombotic thrombocytopenic purpura complicating interferon therapy in chronic C hepatitis. Gastroenterol Clin Biol 32(2):145\u2013146","journal-title":"Gastroenterol Clin Biol"},{"key":"401_CR7","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJM199108083250604","volume":"325","author":"GA Rock","year":"1991","unstructured":"Rock GA, Shumak KH, Buskard NA et al (1991) Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura: Canadian Apherisis Study Group. N Engl J Med 325:393\u2013397","journal-title":"N Engl J Med"},{"key":"401_CR8","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1182\/blood-2008-02-078170","volume":"102","author":"JE Sadler","year":"2008","unstructured":"Sadler JE (2008) Von Willebrand factor, ADAMTS 13, and thrombotic thrombocytopenic purpura. Blood 102:11\u201318","journal-title":"Blood"},{"issue":"7","key":"401_CR9","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1182\/blood-2006-02-006064","volume":"109","author":"S Ferrari","year":"2007","unstructured":"Ferrari S, Scheiflinger F, Rieger M et al (2007) Prognostic value of anti-ADAMTS 13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS 13 activity. Blood 109(7):2815\u20132822","journal-title":"Blood"},{"issue":"3","key":"401_CR10","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1365-2141.2006.06448.x","volume":"136","author":"M Scully","year":"2007","unstructured":"Scully M, Cohen H, Cavenagh J et al (2007) Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13. Br J Haematol 136(3):451\u2013461","journal-title":"Br J Haematol"},{"issue":"1","key":"401_CR11","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1097\/CCM.0b013e31822e9d66","volume":"40","author":"A Froissart","year":"2012","unstructured":"Froissart A, Buffet M, Veyradier A et al (2012) Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French thrombotic microangiopathies reference center. Crit Care Med 40(1):104\u2013111","journal-title":"Crit Care Med"},{"key":"401_CR12","doi-asserted-by":"crossref","first-page":"S88","DOI":"10.1002\/ajh.23126","volume":"87","author":"JN George","year":"2012","unstructured":"George JN (2012) Corticosteroids and rituximab as adjunctive treatments for thrombotic thrombocytopenic purpura. Am J Hematol 87:S88\u2013S91","journal-title":"Am J Hematol"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-013-0401-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11255-013-0401-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-013-0401-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,22]],"date-time":"2020-07-22T19:40:00Z","timestamp":1595446800000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11255-013-0401-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2,24]]},"references-count":12,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["401"],"URL":"https:\/\/doi.org\/10.1007\/s11255-013-0401-7","relation":{},"ISSN":["0301-1623","1573-2584"],"issn-type":[{"value":"0301-1623","type":"print"},{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,2,24]]}}}